Citigroup Upgrades Macrogenics to Buy, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has upgraded Macrogenics (NASDAQ:MGNX) from Neutral to Buy and increased the price target from $7 to $13.
December 20, 2023 | 9:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Macrogenics' stock rating has been upgraded by Citigroup from Neutral to Buy, with the price target raised significantly from $7 to $13.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved prospects for the company. The substantial increase in the price target from $7 to $13 indicates a strong conviction in the company's potential, which could lead to increased investor confidence and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100